{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:43:08Z","timestamp":1768610588538,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.aed.2025.04.005","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:07:53Z","timestamp":1747368473000},"page":"97-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durvalumab-Induced Hypoparathyroidism"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6416-7498","authenticated-orcid":false,"given":"Christopher","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manimegalai","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.aed.2025.04.005_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.aed.2025.04.005_bib2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eprac.2024.03.023","article-title":"Endocrinopathies associated with immune checkpoint inhibitor use","volume":"30","author":"Kotwal","year":"2024","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.aed.2025.04.005_bib3","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.aed.2025.04.005_bib4","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.aed.2025.04.005_bib5","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"issue":"2","key":"10.1016\/j.aed.2025.04.005_bib6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.aed.2025.04.005_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.aed.2025.04.005_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.mayocpiqo.2020.07.006","article-title":"Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"El Kawkgi","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"1","key":"10.1016\/j.aed.2025.04.005_bib9","first-page":"23","article-title":"Pembrolizumab-associated hypoparathyroidism: a single case report","volume":"7","author":"Mahmood","year":"2021","journal-title":"AACE Clin Case Rep"},{"issue":"16_suppl","key":"10.1016\/j.aed.2025.04.005_bib10","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2022.40.16_suppl.2653","article-title":"Immune checkpoint inhibitor-related endocrinopathies: a nationwide population-based study","volume":"40","author":"Elantably","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.aed.2025.04.005_bib11","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EO-22-0047","article-title":"Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab","volume":"2","author":"Kreze","year":"2022","journal-title":"Endocr Oncol"},{"issue":"12","key":"10.1016\/j.aed.2025.04.005_bib12","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"20","key":"10.1016\/j.aed.2025.04.005_bib15","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aed.2025.04.005_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000687","article-title":"Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up","volume":"8","author":"Dadu","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.aed.2025.04.005_bib17","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.aed.2025.04.005_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.aed.2025.04.005_bib19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"69","author":"Bai","year":"2020","journal-title":"Endocrine"},{"issue":"36","key":"10.1016\/j.aed.2025.04.005_bib20","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.aed.2025.04.005_bib21","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:16:35Z","timestamp":1768569395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915725000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S3050915725000244"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.04.005","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab-Induced Hypoparathyroidism","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}